<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="189893">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00621244</url>
  </required_header>
  <id_info>
    <org_study_id>CLBH589B2102</org_study_id>
    <nct_id>NCT00621244</nct_id>
  </id_info>
  <brief_title>A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies</brief_title>
  <official_title>A Phase IA/II, Two-arm, Multi-center, Open-label, Dose-escalation Study of LBH589 Administered Orally Via Different Dosing Schedules in Adult Patients With Advanced Hematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will evaluate safety, tolerability, pharmacokinetics and preliminary
      anti-leukemic or anti-tumor activity of LBH589B in adult patients with advanced
      hematological malignancies
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Establish the maximum tolerated dose and dose-limiting toxicity for two different dosing schedules (MWF weekly or MWF every other week),</measure>
    <time_frame>2.7 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize the safety and tolerability of LBH589 throughout study and up to 28 days after last dose of study drug</measure>
    <time_frame>3.4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">308</enrollment>
  <condition>Lymphoma</condition>
  <condition>Leukemia</condition>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LBH589</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LBH589</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Adult patients (≥18 years old) with advanced hematological malignancies who have
             relapsed after or are refractory to standard therapy, or for which no standard
             therapy exists; or, are considered inappropriate candidates for standard therapy

          -  World Health Organization (WHO) performance status ≤ 2

          -  Patients must meet protocol-specified hematologic and non-hematologic laboratory
             values

          -  Patients must have adequate liver and renal function

        Exclusion criteria:

          -  Concurrent brain metastases or leukemic infiltration of the cerebrospinal fluid

          -  Peripheral neuropathy ≥ CTCAE grade 2

          -  Unresolved diarrhea ≥ CTCAE grade 2

          -  Concurrent severe and/or uncontrolled medical conditions which may compromise
             participation in the study, including impaired heart function or clinically
             significant heart disease, and impaired gastrointestinal function or disease that may
             significantly alter aborption of LBH589

          -  Female patients who are pregnant or breast feeding

          -  Patients not willing to use an effective method of birth control

          -  Patients taking medications specified by the protocol as prohibited for
             administration in combination with LBH589

          -  Patients with another primary malignancy that currently requires active intervention
             or is currently clinically significant

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical College of Georgia</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <lastchanged_date>May 1, 2012</lastchanged_date>
  <firstreceived_date>February 12, 2008</firstreceived_date>
  <firstreceived_results_disposition_date>May 1, 2012</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HDAC inhibitor</keyword>
  <keyword>Oral</keyword>
  <keyword>LBH589</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Panobinostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
